GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Harvard Bioscience Inc (STU:HBI) » Definitions » Cyclically Adjusted PB Ratio

Harvard Bioscience (STU:HBI) Cyclically Adjusted PB Ratio : 1.01 (As of Sep. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Harvard Bioscience Cyclically Adjusted PB Ratio?

As of today (2024-09-22), Harvard Bioscience's current share price is €2.38. Harvard Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was €2.35. Harvard Bioscience's Cyclically Adjusted PB Ratio for today is 1.01.

The historical rank and industry rank for Harvard Bioscience's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:HBI' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.5   Med: 1.26   Max: 2.92
Current: 1.07

During the past years, Harvard Bioscience's highest Cyclically Adjusted PB Ratio was 2.92. The lowest was 0.50. And the median was 1.26.

STU:HBI's Cyclically Adjusted PB Ratio is ranked better than
69.23% of 455 companies
in the Medical Devices & Instruments industry
Industry Median: 2.09 vs STU:HBI: 1.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Harvard Bioscience's adjusted book value per share data for the three months ended in Jun. 2024 was €1.432. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.35 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Harvard Bioscience Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Harvard Bioscience's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Bioscience Cyclically Adjusted PB Ratio Chart

Harvard Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.02 1.49 2.45 0.99 2.04

Harvard Bioscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.01 1.60 2.04 1.63 1.11

Competitive Comparison of Harvard Bioscience's Cyclically Adjusted PB Ratio

For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Bioscience's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Harvard Bioscience's Cyclically Adjusted PB Ratio falls into.



Harvard Bioscience Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Harvard Bioscience's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.38/2.35
=1.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Harvard Bioscience's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book=Book Value per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=1.432/132.5538*132.5538
=1.432

Current CPI (Jun. 2024) = 132.5538.

Harvard Bioscience Quarterly Data

Book Value per Share CPI Adj_Book
201409 2.320 100.428 3.062
201412 2.378 99.070 3.182
201503 2.509 99.621 3.338
201506 2.491 100.684 3.279
201509 2.475 100.392 3.268
201512 2.096 99.792 2.784
201603 2.061 100.470 2.719
201606 1.988 101.688 2.591
201609 1.967 101.861 2.560
201612 1.987 101.863 2.586
201703 1.964 102.862 2.531
201706 1.922 103.349 2.465
201709 1.850 104.136 2.355
201712 1.952 104.011 2.488
201803 1.803 105.290 2.270
201806 1.813 106.317 2.260
201809 1.861 106.507 2.316
201812 1.945 105.998 2.432
201903 1.887 107.251 2.332
201906 1.876 108.070 2.301
201909 1.839 108.329 2.250
201912 1.925 108.420 2.353
202003 1.793 108.902 2.182
202006 1.747 108.767 2.129
202009 1.681 109.815 2.029
202012 1.600 109.897 1.930
202103 1.621 111.754 1.923
202106 1.613 114.631 1.865
202109 1.601 115.734 1.834
202112 1.794 117.630 2.022
202203 1.682 121.301 1.838
202206 1.767 125.017 1.874
202209 1.745 125.227 1.847
202212 1.620 125.222 1.715
202303 1.646 127.348 1.713
202306 1.630 128.729 1.678
202309 1.631 129.860 1.665
202312 1.544 129.419 1.581
202403 1.458 131.776 1.467
202406 1.432 132.554 1.432

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Harvard Bioscience  (STU:HBI) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Harvard Bioscience Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Harvard Bioscience's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Harvard Bioscience Business Description

Traded in Other Exchanges
Address
84 October Hill Road, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.